As a "live drug" different from traditional drugs, CAR-T therapy continues to bring breakthrough surprises to the market in the field of tumor therapy. ScFv is one of the most critical components of CAR-T, and its specificity determines the safety of CAR-T therapy. The off-target safety evaluation of CAR-T drugs is not only a necessary part of preclinical research but also a necessary data for IND application.

In recent years, monoclonal antibody drugs including antibody coupling drugs have been widely used in the treatment of various diseases, but serious clinical side effects caused by missed targets are also common. in the process of antibody drug development, the closer the candidate molecules are to the terminal detection, the higher the price for the development failure. We evaluate the therapeutic antibodies on the market and find that the miss rate of Mabs is 16%....